2023
1102 The HLA-E/NKG2A axis is a dominant immunomodulatory pathway associated with distinct tumor microenvironment features in a subset of NSCLC
Ashley K, Iyer K, Kumar R, Cooper Z, Herbst R, Goldberg S, Schalper K. 1102 The HLA-E/NKG2A axis is a dominant immunomodulatory pathway associated with distinct tumor microenvironment features in a subset of NSCLC. 2023, a1213-a1213. DOI: 10.1136/jitc-2023-sitc2023.1102.Peer-Reviewed Original Research
2018
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 2018, 9: 33995-34008. PMID: 30338041, PMCID: PMC6188056, DOI: 10.18632/oncotarget.26129.Peer-Reviewed Original ResearchLung cancerAdvanced non-small cell lung cancer (NSCLC) patientsNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsSubset of NSCLCWorse overall survivalCell lung cancerLung cancer patientsAnti-tumor effectsNovel therapeutic strategiesNSCLC cell linesTherapeutic paradigm shiftMAPK pathwayUnique therapeutic vulnerabilitiesOverall survivalCancer patientsClinical trialsLung adenocarcinomaKRAS/Therapeutic strategiesPharmacologic inhibitionTherapeutic vulnerabilitiesTherapeutic opportunitiesConcomitant targeting